Ann: Capital Raising Completed, page-43

I would agree raising money within 12 months of listing, at the same price that of IPO is ridiculous to swallow. I would of anticipated a CR around the mid 30's.

I still believe there is huge upside to be had. Prelim results have given holders a glimpse into the potential in months to come when the clinical trials are complete and we move toward FDA submission and approval.

SP has been a slower burn than most would have liked. It is important to remember all that is required is continued validation from these trails. We are on the right path.

Distribution networks are growing globally. The pieces are being put into place for a world wide roll out of sales once validation from a highly respectable source is granted.

I am inclined to say @Gapeseed initial price target of $1 is conservative. All in my option of course.